Jounce Therapeutics' Shares Drop After Baird Downgrade
2:10PM ET 5/11/2022 MT NewswiresShares of Jounce Therapeutics (JNCE) were down almost 19% in Wednesday afternoon trading after Baird downgraded the clinical-stage drugmaker's stock to...
Quotes Snapshot > JNCE
Jounce Therapeutics Inc JNCE:NASDAQ
Last Price$4.69NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/20/22
Today's Change+0.17(3.76%)
Bid (Size)$4.30 (1)
Ask (Size)$5.00 (30)
Day Low / High$4.47 - 4.78
Volume162.3 K
Read more news Recent News
--Baird Downgrades Jounce Therapeutics to Neutral From Outperform, Adjusts Price Target to $7 From $15
7:23AM ET 5/11/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
--Raymond James Upgrades Jounce Therapeutics to Strong Buy From Outperform, Adjusts Price Target to $20 From $15
8:02AM ET 5/06/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
SMBC Nikko Starts Jounce Therapeutics at Outperform With $17 Price Target
4:52AM ET 3/16/2022 MT NewswiresJounce Therapeutics (JNCE) has an average rating of outperform and price targets ranging from $15 to $17, according to analysts polled by Capital IQ. (MT...
View all Commentary and Analysis
Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q1 2022 Results - Earnings Call Transcript
5:25AM ET 5/07/2022 Seeking AlphaJounce Therapeutics (JNCE) Investor Presentation - Slideshow
2:14PM ET 3/07/2022 Seeking AlphaJounce Therapeutics, Inc. (JNCE) CEO Richard Murray On Q4 2021 Results - Earnings Call Transcript
2:16PM ET 3/02/2022 Seeking AlphaJounce Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
10:19AM ET 3/02/2022 Seeking AlphaCompany Profile
Business DescriptionJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its product pipeline includes JTX-2011 (ICOS), JTX-4014 (PD-1), the Lead Macrophage Program, Macrophage Targeting, T Reg, B Cells, and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. View company web site for more details
| Address | 780 Memorial Drive Cambridge, Massachusetts 02139 |
| Phone | +1.857.259.3840 |
| Number of Employees | 115 |
| Recent SEC Filing | 05/05/2022 10-Q |
| President, Chief Executive Officer & Director | Richard Murray |
| Chief Financial Officer & Treasurer | Kimberlee Cobleigh Drapkin |
| Chief Medical Officer | Elizabeth G. Trehu |
| Chief Scientific Officer | Dmitri Wiederschain |
Company Highlights
| Price Open | $4.60 |
| Previous Close | $4.52 |
| 52 Week Range | $4.06 - 9.81 |
| Market Capitalization | $242.4 M |
| Shares Outstanding | 51.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.98 |
| Beta vs. S&P 500 | N/A |
| Revenue | $65.2 M |
| Net Profit Margin | -400.91% |
| Return on Equity | -43.16% |
Analyst Ratings as of 05/10/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |